Avid Bioservices Inc (CDMO)

[JamesGMS]

Sunstar, nice post - we concur with your reasoning. Regarding your statement below:

The IDMC report showed that the Docetaxel + placebo control arm was producing extraordinarily high, even record-breaking, survival results never seen before for Docetaxel in any historical NSCLC clinical trials.

Could you do me a favor? If you have access to the graph initially posted by FTM a few years ago which shows the historical record - I believe for the past 15 years - of trials involving Doxetaxel, I would appreciate it very much if you could repost it for the benefit of Entdoc. From what he mentioned this evening, I don't think he's ever seen the data. Thank you very much.

Also, thanks for reiterating the following in your post:

Peregrine should have a large SUNRISE data set from the unblinded trial for the company and the FDA. These data could also become available to partners.

Currently Peregrine has developing I-O data and a number of quality collaborations that include AstraZeneca, MSK, and the full NCCN.

I think PPHM made exactly the right decision with respect to the SUNRISE trial: Reducing risk by investigating the Doce arm anomaly, and saving both time and money by accelerating the I-O combination collaborations.

James